Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated at HC Wainwright

HC Wainwright initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Monday, MarketBeat.com reports. The brokerage issued a sell rating and a $80.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.53 EPS, FY2024 earnings at $2.30 EPS, Q1 2025 earnings at $2.32 EPS, Q2 2025 earnings at $2.69 EPS, Q3 2025 earnings at $2.75 EPS, Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $10.58 EPS.

SRPT has been the topic of a number of other reports. Citigroup lowered their price target on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Royal Bank of Canada reissued an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. Piper Sandler cut their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, UBS Group raised their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.77.

Sarepta Therapeutics Trading Up 5.7 %

Shares of Sarepta Therapeutics stock opened at $137.94 on Monday. Sarepta Therapeutics has a fifty-two week low of $78.67 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market capitalization of $13.18 billion, a P/E ratio of 110.35 and a beta of 0.81. The company has a fifty day moving average of $122.16 and a 200 day moving average of $131.43.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth $31,000. New Covenant Trust Company N.A. bought a new position in Sarepta Therapeutics during the 1st quarter worth about $32,000. Sunbelt Securities Inc. increased its position in Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank raised its holdings in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Finally, Nkcfo LLC purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $43,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.